The UK will not receive 30 million doses of the vaccine developed by Oxford University and pharmaceutical company AstraZeneca this year, but only 4 million.
The British government’s vaccination task force said so on Monday, writes business newspaper The Financial Times.
The production of those vaccines is not yet taking place in the British Isles either. The first doses of the Oxford vaccine, which has not yet been approved, are produced in the Netherlands and Germany and must be imported.
According to the vaccination task force, the cause of the delay is problems in production in England.
AstraZeneca said, however, that it was decided to produce on the European mainland first because the company had already booked production capacity there.
Competitor Pfizer also previously turned out to be able to supply fewer vaccines this year than it originally wanted. This turned out to be due to problems with the supply of raw materials.
